MERSANA THERAPEUTICS INC. - COMMON STOCK

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

10 Jan 2025 06:02:45 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

10 Jan 2025 06:00:37 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

13 Nov 2024 07:00:50 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

06 Nov 2024 08:00:49 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

13 Aug 2024 07:00:02 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

06 Aug 2024 08:00:14 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Upcoming Investor Conferences

22 May 2024 08:00:49 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

09 May 2024 06:59:34 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 16:30:15 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

02 May 2024 08:00:42 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2024 16:30:28 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

28 Feb 2024 07:00:08 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Upcoming Investor Conferences

27 Feb 2024 08:01:15 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

21 Feb 2024 08:00:22 By Nasdaq GlobeNewswire

Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference

01 Feb 2024 08:00:46 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

05 Jan 2024 08:01:19 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2023 16:30:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

07 Nov 2023 07:00:55 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

31 Oct 2023 16:30:25 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

31 Oct 2023 08:00:01 By Nasdaq GlobeNewswire